Breath of Innovation™

Verona Pharma is developing life enhancing treatments for respiratory diseases.

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company). Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties. Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China.

Find out more

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.

The unmet need

→COPD

Cystic Fibrosis

Asthma

Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the World Health Organization.

Find out more